Thomas J Tolbert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1305461/publications.pdf

Version: 2024-02-01

759233 839539 18 356 12 18 citations h-index g-index papers 18 18 18 413 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effects of Glycan Structure on the Stability and Receptor Binding of an IgG4-Fc. Journal of Pharmaceutical Sciences, 2020, 109, 677-689.	3.3	6
2	Multifaceted assessment of rituximab biosimilarity: The impact of glycan microheterogeneity on Fc function. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 146, 111-124.	4.3	21
3	Photoinduced Tyrosine Side Chain Fragmentation in IgG4-Fc: Mechanisms and Solvent Isotope Effects. Molecular Pharmaceutics, 2019, 16, 258-272.	4.6	15
4	Impact of Glycosylation on the Local Backbone Flexibility of Well-Defined IgG1-Fc Glycoforms Using Hydrogen Exchange-Mass Spectrometry. Journal of Pharmaceutical Sciences, 2018, 107, 2315-2324.	3.3	15
5	Synthesis of a Bifunctional Peptide Inhibitor–IgG1 Fc Fusion That Suppresses Experimental Autoimmune Encephalomyelitis. Bioconjugate Chemistry, 2017, 28, 1867-1877.	3.6	8
6	A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima. Analytical Chemistry, 2017, 89, 4838-4846.	6.5	64
7	Structural characterization of the Man5 glycoform of human IgG3 Fc. Molecular Immunology, 2017, 92, 28-37.	2.2	21
8	Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™. MAbs, 2017, 9, 1197-1209.	5.2	36
9	Correlating the Impact of Well-Defined Oligosaccharide Structures on Physical Stability Profiles of IgG1-Fc Glycoforms. Journal of Pharmaceutical Sciences, 2016, 105, 588-601.	3.3	24
10	Biosimilarity Assessments of Model IgG1-Fc Glycoforms Using a Machine Learning Approach. Journal of Pharmaceutical Sciences, 2016, 105, 602-612.	3.3	11
11	Disulfide bond characterization of endogenous IgG3 monoclonal antibodies using LC-MS: an investigation of IgG3 disulfide-mediated isoforms. Analytical Methods, 2016, 8, 6046-6055.	2.7	11
12	Comparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc Glycoforms. Journal of Pharmaceutical Sciences, 2016, 105, 575-587.	3.3	20
13	Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis. Journal of Pharmaceutical Sciences, 2016, 105, 559-574.	3.3	27
14	Versatile on-resin synthesis of high mannose glycosylated asparagine with functional handles. Carbohydrate Research, 2014, 383, 69-75.	2.3	3
15	Physical Stability Comparisons of IgG1-Fc Variants: Effects of N-Glycosylation Site Occupancy and Asp/Gln Residues at Site Asn 297. Journal of Pharmaceutical Sciences, 2014, 103, 1613-1627.	3.3	31
16	Site-Specific Chemical Modification of a Glycoprotein Fragment Expressed in Yeast. Methods in Molecular Biology, 2011, 751, 329-342.	0.9	2
17	Synthesis of Polymerizable Protein Monomers for Protein-Acrylamide Hydrogel Formation. Biomacromolecules, 2009, 10, 1939-1946.	5.4	15
18	Targeting a Homogeneously Glycosylated Antibody Fc To Bind Cancer Cells Using a Synthetic Receptor Ligand. Journal of the American Chemical Society, 2009, 131, 13616-13618.	13.7	26